Near-Infrared Fluorescence Imaging of EGFR-Overexpressing Tumors in the Mouse Xenograft Model Using scFv-IRDye800CW and Cetuximab-IRDye800CW.
Abolfazl AminiYaghoub SafdariFatemeh Tash ShamsabadiPublished in: Molecular imaging (2022)
EGFR (epidermal growth factor receptor) is overexpressed in a variety of human cancers (including squamous cell carcinoma of head and neck, colon cancer, and some breast cancers) and therefore is regarded as an ideal target for cancer therapy or imaging purposes. In the current study, we produced a scFv-based near-infrared probe (called cet.Hum.scFv-IRDye-800CW) and evaluated its ability in recognizing and imaging of EGFR-overexpressing tumors in a mouse model. Like the molecular probe consisting of its parental antibody (cetuximab, an FDA-approved monoclonal antibody) and IRD800CW, cet.Hum.scFv-IRDye-800CW was able to recognize EGFR-overexpressing tumors in mice. cet.Hum.scFv-IRDye-800CW was found to be superior to the cetuximab-based probe in imaging of mouse tumors. The tumor-to-background ratio and blood clearance rate were higher when cet.Hum.scFv-IRDye-800CW was used as an imaging probe.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- fluorescence imaging
- high resolution
- squamous cell carcinoma
- advanced non small cell lung cancer
- mouse model
- monoclonal antibody
- living cells
- quantum dots
- cancer therapy
- locally advanced
- mass spectrometry
- metabolic syndrome
- adipose tissue
- skeletal muscle
- insulin resistance
- drug administration